Evercore ISI raised the firm’s price target on Penumbra (PEN) to $286 from $285 and keeps an Outperform rating on the shares. The company’s Q3 performance was a standout, beating Wall Street expectations across the board, the analyst tells investors in a research note. The firm added that strong growth in embolization and thrombectomy, coupled with a robust outlook, underscores a promising path forward.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra’s Hold Rating: Balancing Recent Success with Future Uncertainties
- Penumbra price target raised to $355 from $350 at Canaccord
- Penumbra price target raised to $275 from $265 at JPMorgan
- Penumbra’s Strong Financial Performance and Strategic Advancements Reinforce Buy Rating
- Buy Rating for Penumbra: Strong Q3 Performance and Future Growth Catalysts